1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • August 2014
  • -
  • Global Data
  • -
  • 53 pages

Advair (Asthma) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Advair is an FDC of fluticasone propionate and salmeterol xinafoate developed by GSK. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate. Salmeterol xinafoate is a highly selective LABA.

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Advair including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Advair for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Advair performance
- Obtain sales forecast for Advair from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

Advair (Asthma) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis 15
3.1.4 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 20
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 27
6 Advair (fluticasone propionate/salmeterol xinafoate) 31
6.1 Overview 31
6.2 Efficacy 34
6.3 Safety 34
6.4 SWOT Analysis 35
6.5 Forecast 36
7 Appendix 37
7.1 Bibliography 37
7.2 Abbreviations 40
7.3 Methodology 43
7.4 Forecasting Methodology 43
7.4.1 Diagnosed Asthma Patients 43
7.4.2 Percent Drug-Treated Patients 44
7.4.3 General Pricing Assumptions 44
7.4.4 Individual Drug Assumptions 45
7.4.5 Generic Erosion 45
7.5 Physicians and Specialists Included in This Study 46
7.6 About the Authors 49
7.6.1 Author 49
7.6.2 Author/Reviewer 49
7.6.3 Reviewer 50
7.6.4 Global Head of Healthcare 51
7.7 About GlobalData 52
7.8 Disclaimer 52

1.1 List of Tables

Table 1: Symptoms of Asthma 16
Table 2: Treatment Guidelines for Asthma by Country 18
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 19
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 22
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 24
Table 6: Leading Treatments for Asthma, 2014 30
Table 7: Product Profile - Advair 33
Table 8: Efficacy - Advair Diskus Versus Its Individual Components 34
Table 9: Advair, Frequency of Drug-Related Adverse Events 34
Table 10: Advair SWOT Analysis, 2014 35
Table 11: Global Sales Forecast ($) for Advair, 2013-2023 36
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 48

1.2 List of Figures

Figure 1:Stepwise Disease Management Approach for Asthma in Adults 21
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the US

  • February 2017
    9 pages
  • Anti-Infective  

    Influenza  

  • United States  

View report >

Therapy Market in Sweden

  • February 2017
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Contraceptive Market in the Netherlands

  • February 2017
    8 pages
  • Contraceptive  

  • Netherlands  

View report >

Diabetes Statistics

4 days ago

Related Market Segments :

Therapy
Asthma

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.